Hansa Biopharma Ab · OMXSTO:HNSA
Hansa Biopharma Ab — Q4 2025 Earnings Presentation
27 slides from Hansa Biopharma Ab's earnings presentation, Feb 11, 2026
Slide 1: Interim Results January - December 2025
® Interim Results January - December 2025 February 11, 2026
Slide 2: Forward-looking statements
® Forward-looking statements This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will o
Slide 3: Q4 2025 Results Conference Call Agenda
Q4 2025 Results Conference Call Agenda ® 11 February 2026 CEO Remarks Renée Aguiar-Lucander CEO Operational Update Maria Törnsén COO, President US Pipeline Update Richard Philipson Chief Medical Officer Financial Results Evan Ballantyne Chief Financial Officer Close and Q&A Renée Aguiar-Lucander CEO
Slide 4: Key Achievements in Q4 2025
® Key Achievements in Q4 2025 Commercial & Pipeline Business Overview Update Total Q4 revenues 135% increase vs Q4 2024 Q4 IDEFIRIX sales up 139% vs Q4 2024 Q4 revenues: 76.0 MSEK vs 32.3 MSEK Q4 24’ Q4 sales: 61.1 MSEK vs 25.6 MSEK Q4 24’ FY revenues: 222.3 MSEK 30% growth vs 2024 FY product sales
Slide 5: 2025 a year of transformation - Strengthened foundation for 2026
2025 a year of transformation - Strengthened foundation for 2026 ® From Q1 2025 To YE 2025 Strong Balance Sheet Challenging financial situation • Novaquest debt renegotiated • Novaquest debt repayment plan • Equity capital raises => runway into 2027 • Limited cash runway Broad Pipeline Execution Foc
Slide 6: European Commercial Operations Review
European Commercial Operations Review ® Challenging Backdrop Large Growth Potential • Limited clinical data available at • Upcoming topline data from approval PAES • Few European sites involved in • Real world data to be published Phase 2 trial – very limited • ConfIdes data to be presented clinical
Slide 7: USA Market Overview
USA Market Overview ® Large and robust clinical trial Data read out from PAES data available pre-launch study Significant clinical experience Real world data from Europe Pricing determined based on Well researched and market research structured launch plan Centralized organ allocation Experienced, i
Slide 8: Q4 2025 Results Conference Call Agenda
Q4 2025 Results Conference Call Agenda ® 11 February 2026 CEO Remarks Renée Aguiar-Lucander CEO Operational Update Maria Törnsén COO, President US Pipeline Update Richard Philipson Chief Medical Officer Financial Results Evan Ballantyne Chief Financial Officer Close and Q&A Renée Aguiar-Lucander CEO
Slide 9: Idefirix has unique position in Europe: large market with no competition
Idefirix has unique position in Europe: large market with no ® competition OPPORTUNITY No competition – there are no approved desensitization approaches apart from Idefirix 7,000-11,000 Highly Sensitized patients wait 7-12 years for a transplant(1) Highly sensitized patients are less likely to
Slide 10: Q4 delivered Solid Growth with sales registered in all large European markets
Q4 delivered Solid Growth with sales registered in all 5 ® large European markets Performance Market Operational activities Access Arranged large European 61,1M SEK product sales and Progress made regarding Scientific meeting with 72 KOLs 139% growth vs Q4 2024 temporary funding in Catalonia from 17
Slide 11: The US Market Represents a Significant Opportunity
The US Market Represents a Significant Opportunity ® US Transplant Waitlist ~ 15% of patients are highly sensitized (cPRA > 80%) The US represents a significant market opportunity ~100,000 ~15k highly sensitized on the wait list patients with cPRA >80% ~45,000 new additions to the wait list each yea
Slide 12: U.S. launch preparations ongoing to enable H2 2026 launch, assuming approval
U.S. launch preparations ongoing to enable H2 2026 launch, assuming approval ® Concentrated Market Pricing and Reimbursement Pre-launch activities ongoing ~200 adult transplant centers ~55% paid by Medicare Market Access and Distribution Pricing research ongoing; Expansion of field access team in Q1
Slide 13: Q4 2025 Results Conference Call Agenda
® Q4 2025 Results Conference Call Agenda 11 February 2026 CEO Remarks Renée Aguiar-Lucander CEO Operational Update Maria Törnsén COO, President US Pipeline Update Richard Philipson Chief Medical Officer Financial Results Evan Ballantyne Chief Financial Officer Close and Q&A Renée Aguiar-Lucander CEO
Slide 14: The GOOD-IDES-02 Study (21-HMedIdeS-24)
The GOOD-IDES-02 Study (21-HMedIdeS-24) ® Primary Endpoint • Open-label, multi-centre, randomized trial in EU, UK and Renal function as evaluated by eGFR at 6 months US Key Secondary Endpoint • 50 patients randomised 1:1 Proportion of patients with functioning kidney at 6 months, i.e. no dialysis ev
Slide 15: Patient Disposition, Demographics and Baseline Characteristics
® Patient Disposition, Demographics and Baseline Characteristics Full analysis set (N=49) Disposition n (%) Imlifidase SoC Total (N=25) (N=24) (N=49) Randomized 25 (100) 24 (100) 49 (100) Exposed to treatment 25 (100) 24 (100) 49 (100) Completed trial 23 (92.0) 24 (100) 47 (95.9) Discontinued trial
Slide 16: Study Outcomes
® Study Outcomes • The primary endpoint (eGFR at 6 months) and key secondary endpoint (proportion of patients with functioning kidney at 6 months) were not statistically significant • There was no difference in the treatment arms in the proportion of patients with end-stage kidney disease (ESRD) or
Slide 17: Next Steps
® Next Steps • Careful evaluation of study outcomes to see whether there is any benefit in a sub-population • No further clinical trials in anti-GBM • Presentation of study outcomes at a future congress © 2026, Hansa Biopharma AB 17
Slide 18: Q4 2025 Results Conference Call Agenda
® Q4 2025 Results Conference Call Agenda 11 February 2026 CEO Remarks Renée Aguiar-Lucander CEO Operational Update Maria Törnsén COO, President US Pipeline Update Richard Philipson Chief Medical Officer Financial Results Evan Ballantyne Chief Financial Officer Close and Q&A Renée Aguiar-Lucander CEO
Slide 19: YTD 2025 IDEFIRIX Sales Performance
® YTD 2025 IDEFIRIX Sales Performance Revenue (Q/Q) Product Sales (Q/Q) Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 76.0 66.3 49.1 MSEK MSEK 61,1 Product 65,7 32.3 61,1 65,7 30.8 Sales 47,8 47,8 25,6 25,6 30,1 30,1 Contract 14,9 Revenue* 6,7 0.7 1.3 0.7 Revenue (FY/FY) Product Sales,
Slide 20: Continued Investments in R&D & Commercialization
® Continued Investments in R&D & Commercialization SG&A Expenses (Q/Q) R&D Expenses (Q/Q) Operating Loss (Q/Q) Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 -76 -88 -91 -88 -102 -64 -93 MSEK -70 MSEK MSEK -74 -125 -101 -96 -155 -148 -174 SG&A Expenses (FY/
Slide 21: Summary of Cash & Headcount
® Summary of Cash & Headcount Operating Cash Flow (Q/Q) Cash & Cash Equivalents (Q/Q) Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 701 MSEK MSEK -99 -112 405 354 -148 -152 -148 250 252 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 * Pro-forma cash is 888 MSEK including net proceeds from the October 1st capital raise Operating Cas
Slide 22: Q4 2025 Results Conference Call Agenda
Q4 2025 Results Conference Call Agenda ® 11 February 2026 CEO Remarks Renée Aguiar-Lucander CEO Operational Update Maria Törnsén COO, President US Pipeline Update Richard Philipson Chief Medical Officer Financial Results Evan Ballantyne Chief Financial Officer Close and Q&A Renée Aguiar-Lucander CEO
Slide 23: Summary
Summary ® Strong foundation created Clear roadmap Key inflection points during 2026 Execution focus Experienced team © 2026, Hansa Biopharma AB 23
Slide 24: Highly experienced leadership team
Highly experienced leadership team Proven track record delivering growth, approvals, and launches across renal, rare disease, and immunology ® Renée Aguiar-Lucander Maria Törnsén CEO COO, President US 20+ yrs rare disease leader and former investor, took Successfully launched multiple orphan drugs i
Slide 25: Q&A
® Q&A © 2026, Hansa Biopharma AB 25
Slide 26: Hansa Biopharma contacts and key events
® Hansa Biopharma contacts and key events Contacts Calendar and Events 2026 Evan Ballantyne 2 MAR TD Cowen 46th Annual Healthcare Conference, Boston Chief Financial Officer Email: ir@hansabiopharma.com 9 MAR Leerink Partners Global Healthcare Conference 2026, Miami 10 MAR Jefferies, Biotech on the B
Slide 27: HAN Sar
IZ HAN Sar BIOPHARMA